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Introduction
Colon cancer is one of the leading malignant diseases 
worldwide. In 2014, there were approximately 100,000 
new colon cancer cases expected in the US. As in other 
types of cancer, the prognosis strongly depends on the 
stage of the disease. In addition to the Dukes classifica-
tion, the UICC scheme gained general acceptance and is 
widely used for prognosis estimation and therapy strati-
fication [1]. Healing from cancer is attempted in all cases 
without distant metastases, which belong to UICC stages 
I–III. However, a curative therapeutic approach in meta-
static disease is possible only in a certain number of cases. 
Among those cases, the node negative cases are classified 
as stage I or II, depending on the infiltration depth. These 
patients are known to have an excellent prognosis [2]. 
Adjuvant chemotherapy promises only a small benefit in 
these cases [3] and is therefore restricted to particular 
risk situations [2]. Nevertheless, approximately 10% to 
20% of colon cancer cases show an adverse clinical course. 
To date, there is no generally accepted diagnostic tool 
available that could predict which of those cases are prone 
to developing progressive disease. Many authors suggested 
false node negativity and stage migration to explain the 
aggressive behavior of certain stage II cancers [4, 5]. 
However, we and others recently could show that nodal 
understaging is most likely an overestimated problem and 
occurs only in a small portion of cases. These reports 
could disprove that the prognostic strength of the UICC 
staging could be heightened by improving lymph node 
retrieval and detection of lymph node metastases. The 
NCCN defined several additional factors to identify patients 
at an increased risk for progressive disease in stage II 
colorectal cancers [2]. These factors include T4 stage, 
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Abstract
A portion of stage I/II colon cancers (10–20%) exhibit an adverse clinical course. 
The administration of adjuvant chemotherapy is recommended only in certain 
high- risk situations. However, these risk factors recently failed to predict benefit 
from adjuvant therapy. We composed a new morphology- based risk score that 
includes pT1/2 versus 3/4 stage, vascular or lymphovascular invasion, invasion 
type according to Jass, tumor budding and paucity (less than two) of lymph 
nodes larger than 5 mm. The occurrence of each of these factors accounts for 
one point in the score (Range 0–5). This score was evaluated in a retrospective 
study that included 301 cases. The overall survival differed significantly between 
the three groups with median survival times of 103, 90, and 48 months,  respectively. 
Multivariable analysis revealed morphology- based risk—high risk and low risk—as 
the sole independent factors for the prediction of death. Morphology- based risk 
scoring was superior to microsatellite status and NCCN risk stratification. This 
method identifies a group of patients that comprises 18% of the stage II cases 
with an adverse clinical course. Further studies are necessary to confirm its 
prognostic value and the possible therapeutic consequences.
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inadequate lymph node harvest, emergency situation, and 
obstruction. Several attempts have been made to establish 
risk stratification systems based on molecular testing. To 
date, only testing for microsatellite instability received a 
recommendation by the NCCN. Gene microarrays were 
developed in analogy to their use in breast cancer. These 
tests could be shown to be prognostically independent of 
the established factors of the TNM system [2, 6, 7]. 
Nevertheless, the evidence for these tests seems insufficient 
for a general recommendation. The drawbacks of molecular 
testing are the high costs, and the need for fresh tumor 
tissue for the ColoPrint® test. A promising concept to 
distinguish prognostically different subgroups of colon 
cancer has been introduced by Galon et al. that is based 
on the evaluation of the immune response against the 
tumor. An immune score is calculated by counting the 
number of CD3- and CD8- positive T- lymphocytes in 
the tumor center and at the invasion front. A large inter-
national prospective multicenter trial is currently underway 
to evaluate this concept [8, 9].
As an alternative approach to sophisticated molecular 
tests, we hypothesized that a risk score based on a panel 
of histological features could provide additional informa-
tion to predict the clinical course of stage I/II colorectal 
cancer more precisely than UICC staging alone. It was 
our goal to establish a score that it is easy to evaluate 
without the need for extra time and costs. The selection 
of the factors was based on the experiences of different 
previously performed studies [10–12] and on the idea of 
including factors that represent various aspects of tumor 
progression. For this morphology- based risk (MBR) score, 
we included T- stage and vascular and lymphovascular 
invasion as established factors of the TNM classification 
system. Additionally, tumor budding and invasion type 
according to Jass [13] were included. The fifth factor is 
the paucity of intermediate to large sized lymph nodes, 
which recently has been proposed as a new prognostic 
factor in colon cancer. Paucity in this context is defined 
as less than two lymph nodes with a diameter larger than 
5 mm. We could demonstrate that the number of lymph 
nodes larger 5 mm (LN5) is associated with lymph node 
count and outcome [10]. Moreover, we reported an asso-
ciation between this factor and lymphocytic tumor infil-
tration, which indicate that LN5 could serve as a surrogate 
marker for immune response.
Materials and Methods
Patients
Cases from 2002 to 2005 and from 2007 to 2010 were 
retrieved from our files. The cases from the first period 
belong to an era where conventional lymph node 
dissection was performed. Since 2007, the methylene blue- 
assisted lymph node dissection technique was routinely 
used. The cases from 2006 were excluded because the 
specimens were dissected in very different ways and by 
a high number of differently qualified staff (pathologists, 
residents, technicians). The study cases were retrieved by 
a search within the administrative database (Nexus AG, 
Frankfurt am Main, Germany) of the Institute of Pathology.
Inclusion criteria were stage I/II colon cancers, curative 
intention, and a minimal follow- up period of two months. 
Criteria of exclusion were positive resection margins and 
clinical or histologic evidence of metastatic disease. 
Follow- up data were provided by the Clinical and 
Population based Cancer Registry Augsburg. This register 
is responsible for the region of Swabia with 1.8 million 
inhabitants. It receives cancer- and patient- related infor-
mation from all hospitals and from practicing oncologists. 
Importantly, it can match their data with the deaths in 
the region. Additionally, the clinical information system 
and the files of the pathology department were screened 
for more case- related information. A flowchart that out-
lines the patient selection is given in Figure 1. The study 
Figure 1. Selection of cases after research for node negative colon 
cancers within the files of the Institute of Pathology of the Klinikum 
Augsburg.
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was performed according to the national rules and approved 
by the internal review board of the Klinikum Augsburg.
Histopathological evaluation, morphometry, 
and immunohistochemistry
Factors and scoring of the MBR- score are shown in Table 1. 
All histopathological factors of the MBR- score were evalu-
ated on hematoxylin- and eosin- stained slides. No immu-
nohistochemistry was performed, except for the evaluation 
of the mismatch repair genes. Tumor budding was defined 
as positive in cases where more than 30 tumor buds of 
≤ 5 cells were identified at the invasion front in a field 
of 1.22 mm² (Fig. 2A). The invasion type (Fig. 2B) was 
evaluated according to the definition by Jass. All cases 
were re- evaluated by two independent pathologists (BM 
and TS) who read one tumor slide blinded to the original 
reports and the case- related information. In cases of dis-
crepancy, a consensus diagnosis on a double- headed 
microscope was made using additional slides.
For the comparison of the significance of MBR- score 
with the established criteria of the NCCN guideline, the 
occurrence of one or more of the following criteria was 
classified as high- risk situation: lymphatic/vascular inva-
sion, tumor perforation (= pT4), poor lymph node harvest 
(<12 LNs), poor differentiation, and perineural invasion. 
Cases with positive or indeterminate resection margins 
were not included in the study as mentioned above [2].
The morphometric analysis of lymph nodes to determine 
the number of LN5- nodes was performed using either a 
digital camera with a calibrated software system (progress 
C3, Jenoptik, Wetzlar, Germany) (93 cases) or a simple 
caliber with a 5 mm punch (208 cases), as described 
previously [10, 11].
In all cases where at least one of the Bethesda criteria 
regarding Lynch syndrome was fulfilled, microsatellite 
diagnostics, including comparative PCR analysis of the 
loci of the consensus panel and immunohistochemistry 
for the mismatch repair genes MLH1, MSH2, MSH6 and 
PMS2, were performed. Additionally, all cases with med-
ullary features or mucinous carcinomas were immuno-
histochemically stained for MLH1. In these cases, grading 
depended on the microsatellite status. Moreover, MLH1 
expression was evaluated in 127 additional cases of the 
cohort that were not suspicious for a lynch syndrome 




pT3/4 - Stage 0 low
Infiltrative invasion type 
Tumor budding 1–2 intermediate
Vascular invasion (V1 and/or L1)
<2 LN5 3–6 high
Figure 2. (A) HE, 16x; Colon carcinoma with infiltrative invasion pattern. The muscularis propria is dissected by streaming atypical tumor glands. 
(B) HE, 50x; Same case with infiltration of the mesenteric fat with relatively little stromal response. (C) HE, 16x; Invasion front of a colon cancer with 
extensive tumor budding. (D) HE, 100x; Same case with higher magnification.
A B
C D
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and had no mucinous or medullary differentiation to 
enrich the number of cases with known mismatch- repair 
status. Immunostaining was performed as described previ-
ously [10].
Outcome measurements and subgroups
Overall survival was chosen as the endpoint for the out-
come comparison. It was defined as the time between 
operation and death. Comparisons were performed between 
the three MBR- score groups (Table 1) in UICC stage I/II 
cancers and separately for each of the two stages. Further 
analysis was performed in 151 microsatellite stable cases 
to exclude confounding by microsatellite instability. 
Additional comparisons were performed between cancers 
without and with at least one NCCN- risk factor.
Statistics
Depending on the results of normality testing, metric 
values were compared using either the student’s t- test or 
the Mann–Whitney rank sum test. Dichotomous data were 
analyzed with the χ² test or Fisher’s exact test, depending 
on the sample size. For the evaluation of interobserver 
agreements, Cohen’s kappa coefficient was calculated. For 
the determination of the median follow- up time, the 
method of Schemper and Smith was used [14].  Ka plan–Meier 
curves were created, and log- rank regression analysis were 
performed to compare overall and tumor- related survival 
of the different groups. Multivariable analysis was per-
formed using the Cox regression proportional hazards 
model. P < 0.05 were considered to be significant. All 
calculations were performed using the Sigma- Plot 13.0 
software package (Systat, Erkrath, Germany).
Results
Patients, study groups and interobserver 
agreement
We included a total of 301 cases. The low, intermediate, 
and high groups comprised of 64, 208, and 29 cases, 
respectively. The clinicopathological data are summarized 
in Table 2. The two significantly different factors are pT- 
stage and location. MBR high- risk cancers are all locally 
advanced pT3/4 cases that occur primarily in the left 
colon. These patients tend to be older (72 vs. 70 and 
68 years; P = 0.11). From 17 tumors with known MMR- 
status, 16 were classified as MMR proficient (94%). 
Comparison between the evaluation results from the two 
pathologists showed moderate agreement for the factors 
vascular invasion (κ = 0.41) and invasion type (κ = 0.56). 
Table 2. Clinicopathological data.
 Low n = 64 Intermediate n = 208 High n = 29 P- Value
Mean Age ± SD 68 ± 10 70 ± 10 72 ± 12 P = 0.11
Age <50 3 (5%) 9 (4%) 2 (7%) P = 0.83
Gender m: f 1: 0.7 1: 0.7 01:01 P = 0.78
Mean LN count ± SD 22 ± 14 21 ± 15 20 ± 13 P = 0.51
LN count <12 8 (8%) 39 (19%) 6 (21%) P = 0.47
Conventional Adenocarcinoma 57 (89%) 176 (85%) 27 (93%)
Mucinous type 5 (8%) 22 (11%) 1 (3%)
Medullary type 1 (2%) 8 (4%) 1 (3%)
Other Types 1 (2%) 2 (1%) 0 (0%) P = 0.362
pT1 13 (20%) 15 (7%) 0 (0%)
pT2 51 (80%) 55 (26%) 0 (0%)
pT3 0 132 (63%) 26 (90%)
pT4 0 6 (3%) 3 (10%) P = 0.0013
Low grade 55 (86%) 160 (77%) 21 (72%)
High Grade 9 (14%) 48 (23%) 8 (28%) P = 0.220
Right sided 43 (67%) 102 (49%) 10 (34%)
Left sided 21 (33%) 106 (51%) 6 (21%) P = 0.006
MSS1 30 (75%) 105 (86%) 16 (94%)
MSI1 10 (25%) 17 (14%) 1 (6%) P = 0.125
Chemotherapy adj. 0 15 (7%) 3 (10%) P = 0.06
Chemotherapy—adj. and pal. 1 (2%) 24 (12%) 7 (24%) P < 0.001
SD = standard deviation, LN = lymph node, MSS = microsatellite stabile, MSI = microsatellite instable.
1microsatellite stability data were available only in 179 cases.
2analysis compared conventional versus the three other categories,
3only the pT stages of the intermediate and the high- risk groups were compared, adj. = adjuvant, pal. = palliative.
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Substantial agreement was achieved for the factors tumor 
budding (κ = 0.61), lymphovascular invasion (κ = 0.66) 
and T-stage (κ = 0.75).
The distribution of worse factors in the 
high- risk group
To identify the factors that contributed most frequently 
to a MBR high- risk score, the different combinations of 
worse factors were counted. As mentioned above, all cases 
in the high- risk group show an infiltration beyond the 
muscularis propria (pT3/4). The group of MBR high- risk 
cases consists of 23 cases with a MBR score of 3, four 
cases with a MBR score of 4, and two cases with a MBR 
score of 5. The combination of the other worse risk fac-
tors in the MBR score 3 category is given in Table 1. 
Out of the 29 total cases classified as MBR high risk, 
tumor budding and LN5 classification were found in 23 
(79%) and 18 (62%) cases, respectively. The most fre-
quently found combination was pT3/4, tumor budding, 
and LN5vl (Fig. 3). This indicates that the latter two 
factors are of special importance in stage II cancers.
MBR score- related survival
The median time for which the patients were followed 
was 60 months (range: 2–143 months). The classifica-
tion of stage I/II colon cancers according to the MBR 
score reveals three highly significantly different prognostic 
groups (P < 0.001) (Fig. 4). The median overall survival 
times were 103 months (95% Confidence Interval (CI): 
98–107 months), 90 months (CI: 79–101 months), and 
48 months (CI: 37–59) for the low- , intermediate- , and 
high- risk group, respectively (Fig. 4A). This finding held 
true when the analysis was restricted to stage II colon 
cancers with median survival times of 90 months (CI: 
80–102) and 48 months (CI: 37–59 months), P < 0.001 
(Fig. 4C) for the intermediate- and the high- risk group, 
respectively. Note that the low- risk group includes no 
stage II cancers as per definition. A subgroup analysis 
concerning stage I cancers showed that none of these 
cases belonged to the MBR high- risk score. Nevertheless, 
the comparison of low- and intermediate- risk cases 
revealed a significant worse clinical course of the 
intermediate- risk group. The corresponding survival 
times were 100 months (CI: 50–150) and 68 months 
(CI: 52–84) for the low- risk and the intermediate- risk 
group, respectively (Fig. 4D).
MSS stratified survival, comparison with 
NCCN risk stratification, and multivariable 
analysis
MBR scoring was also prognostic when only cases with 
a known microsatellite stability status were analyzed. The 
corresponding median overall survival times were 
103 months (CI: 80–126 months), 87 months (CI: 
75–99 months), and 44 months (CI: 9–79 months), 
P < 0.001 for the low- , intermediate- , and high- risk group, 
respectively. (Fig. 4B). The occurrence of at least one 
NCCN risk factor was associated with a highly significant 
worse outcome with median overall survival times of 
91 months (CI: ± inf) versus 77 months (CI: 
54–73 months), P = 0003 (Fig. 4E). However, the dis-
crimination between the different prognostic groups is 
considerably weaker compared to MBR scoring. The dis-
tribution of risk stages based on NCCN and MBR score 
stratification is shown in Figure 5.
For a multivariable analysis of the whole study collec-
tive (stage I/II), the individual factors of the MBR- score 
(pT stage, vascular invasion, lymphovascular invasion, 
invasion type, tumor budding, and LN5vl), the MBR stage, 
grading, and the microsatellite status were chosen because 
these factors are widely accepted as being prognostic. Cox 
regression proportional hazards model analysis revealed 
that MBR- high risk and low risk were the sole independ-
ent factors for the prediction of death with hazard ratios 
of 4.12 (CI: 2.20–7.8) and 0.4 (CI: 0.18–0.9), respectively. 
Additional analysis performed in a subgroup of stage II 
cases with the additional inclusion of NCCN risk factor 
stratification also revealed that MBR high risk was the 
only predictive factor for overall survival (HR: 4.35; CI: 
2.19–8.62).
Figure 3. Distribution of worse factors in MBR score 3 cases. All cases 
showed an infiltration of the mesenteric fat or the serosal layer. LN = 
less than 2 lymph nodes were identified; B  =  Tumor budding; 
I = infiltrative invasion type; V/L vascular or lymphovascular invasion. 
The paucity of LN5 and tumor budding were the most frequent factors 
contributing to the high- risk situation.
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Figure 4. Overall survival analysis: (A) stratified according to MBR scoring including all cases (stage I and II), (B) stratified according to MBR scoring in 
the subgroup of microsatellite stable cases, (C) stratified according to MBR scoring restricted to stage II cases, (D) stratified according to MBR scoring 
restricted to stage II cases, (E) stratified according to occurrence of NCCN risk factors in stage II cases.
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Discussion
Several attempts were made to improve the risk stratifica-
tion in localized colon cancer. Under several developed 
multigene assays, Oncotype DX colon and ColoPrint gained 
the most recognition. Oncotype DX is a 12- gene assay 
that proved to be independently prognostic (hazard rate 
1.38) but not predictive when it was used on formalin- 
fixed, paraffin- embedded stage II cancers from the 
QUASAR trial [6]. In contrast, fresh tissue is needed for 
the ColoPrint assay that includes 18 genes. Compared to 
other factors, this assay also independently discriminates 
between low- and high- risk cases and was shown to be 
an independent predictor of distant metastases with a 
hazard ratio of 4.28 [7]. However, multigene assays are 
not recommended by the NCCN guideline 2015 because 
of lacking data that advocate adjuvant chemotherapy in 
high- risk situations. [2]. Based on an extensive hypoxia- 
driven gene expression analysis, Dekervel et al. develop 
a six- gene score that could be shown to be prognostic 
in stage II and III colon cancers [15]. Molecular classi-
fications have been introduced by Jass [16] and very 
recently with a very comprehensive approach by a large 
group of international experts [17]. A different approach 
is the evaluation of the host’s immune response to the 
tumor. Galon et al. developed an “Immuno” score that 
is based on the immunohistochemical evaluation of the 
densities of CD3- and CD8- positive T- lymphocytes in the 
tumor center and at the invasion front. The authors could 
show that its prognostic value is superior to conventional 
TNM staging [18].
With the exception of MSI testing, none of these inno-
vative and sophisticated tests achieved broad clinical accept-
ance or even recommendation by relevant authorities yet 
[2]. The benefit of adjuvant chemotherapy in localized 
colon cancer is notably small and is therefore restricted 
to high- risk situations that have been defined by the NCCN 
[3, 19–21]. However, a large study based on 24,847 patients 
from the Surveillance, Epidemiology, and End Results 
(SEER) database found no benefit for stage II cancers with 
or without these risk factors [22]. Therefore, there was a 
demand to define more accurate risk factors to identify 
high- risk patients who potentially could benefit more from 
adjuvant therapy [23, 24]. Based on this situation, we had 
the idea to follow an apparently old- fashioned approach 
to developing a test solely based on H&E morphology. In 
this retrospective study, we could show that the MBR score 
can discriminate among three prognostic groups of stage 
I/II colon cancers with a hazard ratio of 4.12 for the high- 
risk group. This was independent of other risk factors and 
also held true in a subgroup of microsatellite cancers. The 
comparison of clincopathological factors showed a higher 
rate of left- sided cancers, microsatellite stable and locally 
advanced cancers in the MBR high- risk group (Table 2). 
These features could be an indication that the biology of 
these tumors differs fundamentally. Noteworthy, the mean 
age of the patients in the high- risk group was higher than 
in the other groups (72 vs. 70 and 68 years) which is a 
potential bias concerning the overall survival analysis.
As mentioned before the basic selection criteria for the 
individual factors were easiness of its evaluation and their 
prognostic relevance. The score is composed of factors 
of the TNM system (pT stage and L/V classification), 
additional well- investigated prognostic factors (invasion 
type and tumor budding), and a new prognostic factor 
(LN5 classification). The prognostic relevance of the infil-
tration depth and lymphovascular and vascular invasion 
has been confirmed in many studies [25–27]. Both factors 
are integral components of the TNM classification [28]. 
They are visible signs of advanced local extension and 
connection to the vascular system as a requirement for 
distant spread. The additional factors invasion type and 
tumor budding are well known, but did not achieve rec-
ommendation in national guidelines [2, 29]. The infiltrative 
invasion type is associated with aggressive behavior [30]. 
However, the interobserver agreement is less than optimal 
Figure 5. Distribution of risk groups in stage II colon cancers. Note. 
18% of cases were graded high- risk according to the MBR scoring while 
49% of cases showed at least one NCCN risk factor.
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[13] and it seems that difficulties in interpreting the his-
tological features from Jass’ method led to an overdiagnosis 
of this feature with a loss of prognostic strength. In our 
opinion, this invasion type occurs in no more than 10% 
to 15% of cases (Fig. 1B). Tumor budding has been 
investigated in many studies as a prognostic factor for 
tumors of the gastrointestinal tract [31]. Unfortunately, 
this feature is hampered by several different competing 
definitions, cutoffs, and methods of evaluation. A recently 
performed study revealed only a fair interobserver agree-
ment among 10 investigators [32]. The interobserver 
agreement in this study was substantial with a κ- value 
of 0.61. Nevertheless, regardless of the way tumor bud-
ding is judged, the vast majority of studies confirmed an 
association between tumor budding and other worse fac-
tors such as lymph node metastases and aggressive clinical 
course [31]. Tumor budding is believed to reflect epithelial 
mesenchymal transition which promotes tumor cell migra-
tion and tumor progression [33]. The WNT/Wingless 
signaling pathway is involved in this process of epithelial 
mesenchymal transition by influencing β- catenin and 
E- cadherin [34, 35]. Therefore, it seems to be a relevant 
morphologic adjunctive factor that reflects a certain 
molecular feature that promotes tumor progression. Lymph 
node size is the most recently introduced prognostic fac-
tor and is associated with lymph node yield and outcome 
[11, 36]. Our group demonstrated that the paucity of 
lymph nodes with diameters >5 mm, termed LN5vl, is 
an independent prognostic factor in conventional lymph 
node dissected colon cancer [10] and after employment 
of advanced dissection techniques. We believe that this 
factor can serve as a surrogate marker for an impaired 
immune response [37]. Along with the fact that LN5vl 
is extremely easy to determine, this makes it an ideal 
complement to previously established factors. A problem 
of NCCN risk factor stratification could be that a high 
proportion of tumors show at least one worse feature. 
In our analysis, 81 of 165 stage II cancers fell into this 
category. Compared to a rate of 10% to 20% of cases 
that show an aggressive course, this proportion seems to 
be too high. The MBR high- risk group comprises only 
10% of stage I/II cases and 17% of stage II cancers which 
seem more appropriate. In comparison to the NCCN risk 
stratification, its prognostic strength is higher (Fig. 3C 
and 3E).
Without a doubt, morphological stratification is ham-
pered by the subjectivity of the investigator. On the other 
hand, it is unbeatable regarding costs, efforts, and avail-
ability. It is an interesting question whether the future 
of cancer stratification will be molecular or morphologic. 
It could be a smart approach to combine the best of two 
worlds. Such an attempt has already been made by 
Srivastava et al. in hepatocellular carcinoma [38].
In conclusion, the MBR score includes morphological 
factors that reflect the extension of local spread, angioin-
vasion, epithelial mesenchymal transition, aggressive phe-
notype, and immune response. In this retrospective analysis, 
the MBR score was the only independent prognostic factor 
regarding overall survival in stage I/II colon cancers. Future 
clinical consequences that could be drawn are that an 
intensified surveillance could be recommended for the 
patients of the intermediate- risk group. However, patients 
of the high- risk group could benefit from adjuvant chemo-
therapy. We are currently planning to perform a multi-
center study restricted to stage II colon cancer to verify 
the findings of this study in a prospective design.
To answer the question of whether these high- risk 
patients could benefit from adjuvant chemotherapy, a 
considerably larger study with a prospective design is 
necessary.
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